Nature CommunicationsBiochemistryPeer-reviewed journal article
Biosynthetic Enzyme-guided Disease Correlation Connects Gut Microbial Metabolites Sulfonolipids to Inflammatory Bowel Disease Involving TLR4 Signaling
E. A. Older, J. Zhang, Z. E. Ferris, D. Xue, Z. Zhong, M. K. Mitchell, M. Madden, Y. Wang, H. Chen, P. Nagarkatti, M. Nagarkatti, D. Fan, M. Ellermann, Y. LIiD, J. Li
Abstract
The trillions of microorganisms inhabiting the human gut are intricately linked to human health. At the species abundance level, correlational studies have connected specific bacterial taxa to various diseases. While the abundances of these bacteria in the gut serve as good indicators for disease progression, understanding the functional metabolites they produce is critical to decipher how these microbes influence human health. Here, we report a unique biosynthetic enzyme-guided disease correlation approach to uncover microbial functional metabolites as potential molecular mechanisms in human health. We directly connect the expression of gut microbial sulfonolipid (SoL) biosynthetic enzymes to inflammatory bowel disease (IBD) in patients, revealing a negative correlation. This correlation is then corroborated by targeted metabolomics, identifying that SoLs abundance is significantly decreased in IBD patient samples. We experimentally validate our analysis in a mouse model of IBD, showing that SoLs production is indeed decreased while inflammatory markers are increased in diseased mice. In support of this connection, we apply bioactive molecular networking to show that SoLs consistently contribute to the immunoregulatory activity of SoL-producing human microbes. We further reveal that sulfobacins A and B, two representative SoLs, primarily target Toll-like receptor 4 (TLR4) to mediate immunomodulatory activity through blocking TLR4s natural ligand lipopolysaccharide (LPS) binding to myeloid differentiation factor 2, leading to significant suppression of LPS-induced inflammation and macrophage M1 polarization. Together, these results suggest that SoLs mediate a protective effect against IBD through TLR4 signaling and showcase a widely applicable biosynthetic enzyme-guided disease correlation approach to directly link the biosynthesis of gut microbial functional metabolites to human health.
- organism: human
- assay: metabolomics
- research focus: host-pathogen & immune response
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A meta-analysis of the gut microbiome in inflammatory bowel disease patients identifies disease-associated small molecules
Moamen M. Elmassry, Kohei Sugihara, … Mohamed S. Donia·bioRxiv·Feb 7, 2024
- Systematic Mining of gut microbiota biomarkers for IBD
Yuchen Zhang, Wenkai Lai, … Fenglong Yang·bioRxiv·Oct 10, 2024
- Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome
A. Pearl, H. Bootz, … N. Yissachar·bioRxiv·Aug 15, 2021
- Human-derived microRNA 21 regulates indole and L-tryptophan biosynthesis transcripts in a prominent gut symbiont
Kayla Flanagan, Kirsten Gassner, … Fátima C. Pereira·mBioPeer-reviewed·Jan 29, 2025
- A gut pathobiont synergizes with the microbiota to instigate inflammatory disease marked by immunoreactivity against other symbionts but not itself
J. C. Gomes-Neto, H. Kittana, … A. E. Ramer-Tait·bioRxiv·Aug 18, 2017
- Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease
S. Hu, A. R. Bourgonje, … R. K. Weersma·bioRxiv·Jun 4, 2022